Oncternal to Lay Off 37% of Employees, Including CMO

Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales or an M&A.
To reduce operating expenses while it considers “strategic alternatives” for its future, Oncternal Therapeutics is laying off about 10 employees, representing roughly 37% of its workforce, according to a Sept. 12 SEC filing. In connection with that reduction, Salim Yazji will be out as chief medical officer, effective Oct. 1.